Currently Viewing:
Supplements Best Practices for Treating Parkinson’s Disease: A Focus on Symptoms and Considerations for Manage
The Economic and Quality of Life Burden Associated With Parkinson's Disease: A Focus on Symptoms
Deborah F. Boland, DO, MSPT, and Mark Stacy, MD
Early Treatment of Parkinson's Disease: Opportunities for Managed Care
Daniel L. Murman, MD, MS, FAAN
Improving Outcomes Through Early Diagnosis of Parkinson's Disease
Fernando L. Pagán, MD
Currently Reading
Participating Faculty: Best Practices for Treating Parkinson's Disease: A Focus on Symptoms and Considerations for Managed Care

Participating Faculty: Best Practices for Treating Parkinson's Disease: A Focus on Symptoms and Considerations for Managed Care

This supplement to The American Journal of Managed Care reviews the economic and quality of life burden associated with Parkinson’s disease (PD). The rationale behind the early diagnosis and treatment of PD is also discussed, with a focus on recognition of nonmotor symptoms of PD and the implications for early therapeutic intervention.
This supplement was supported by UCB, Inc.

Faculty

Deborah F. Boland, DO, MSPT

Fellow
Movement Disorders Center
Division of Neurology
Department of Medicine
Duke University
Durham, North Carolina

Daniel L. Murman, MD, MS, FAAN
Director of Behavioral and Geriatric Neurology Program
Associate Professor
Department of Neurological Sciences
University of Nebraska Medical Center
Omaha, Nebraska

Fernando L. Pagán, MD
Director of Movement Disorders Program
Associate Professor of Neurology
Department of Neurology
Georgetown University Hospital
Washington, DC

Mark Stacy, MD
Professor of Neurology
Vice Dean for Clinical Research
Division of Neurology
Department of Medicine
Duke University
Durham, North Carolina

Disclosures 
These faculty report relationships with the following organizations:

Fernando L. Pagán, MD
Consultant/advisory board: Allergan, Avanir, GlaxoSmithKline, Ipsen, Medtronic, Teva Neuroscience, US WorldMeds
Grants: Medtronic, Teva Neuroscience

Mark Stacy, MD
Consultant: Allergan, Chelsea, General Electric, GlaxoSmithKline, Merck, Merz, Neuronova, Novartis, Noven, Osmotica, SK Life Sciences, Teva, UCB Grant/research support: Ceregene, IMPAX, Michael J. Fox Foundation, National Institutes of Health, Novartis, Parkinson Study Group
Protocol steering committee: Allergan, EMD Serono, Teva
Royalties: Informa Press (publisher of Handbook of Dystonia)
Safety monitoring board: Neurologix

Deborah F. Boland, DO, MSPT, and Daniel L. Murman, MD, MS, FAAN, report no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this supplement.

Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.


Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.
PDF
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up